Drug Profile
Sarpogrelate controlled release - Alvogen Korea
Alternative Names: KW-21027Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator KunWha Pharmaceutical
- Developer Alvogen Korea
- Class Antiplatelets; Butyric acids; Dimethylamines; Succinates; Vascular disorder therapies
- Mechanism of Action Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Arterial occlusive disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Arterial-occlusive-disorders (In volunteers) in South Korea (PO, Controlled release)
- 18 May 2016 Chemical structure information added